Novel Photodepletion Strategy to Preserve and Expand Tregs While Eliminating CD4+ Effector T Cells From Patients with Chronic Graft-Versus-Host Disease
Bibliographic record
Abstract
Abstract Abstract 353 Even the most potent immunosuppressive drugs often fail to control graft-versus-host disease (GVHD), the most frequent and deleterious post-transplantation adverse condition. The development of a strategy to eliminate alloreactive T cells and spare regulatory T cells (Tregs) would provide a direly needed therapeutic option for patients with refractory GVHD. We previously reported that photodepletion using dibromorhodamine (TH9402) eliminates T cells from healthy donors activated against major histocompatibility complex (MHC)-incompatible cells and spares resting T cells. In the present study, we identified novel photodepletion conditions (1.32 μM TH9402, 45 minutes incubation, and 5 J/cm2 light delivery at 514 nm) selectively eradicating 60–90% of endogenous proliferating host T cells as measured by 3H-thymidine incorporation, and CD4+CD25+FOXP3- effector memory phenotype cells (p<0.001) from chronic GVHD patient cells, with concomitant sparing of the majority of CD4+CD25+FOXP3+ Tregs. All GVHD patients tested (n=10) had severe extensive chronic disease and were refractory to at least 2 immunosuppressive agents. Preservation of Treg function after photodepletion was confirmed by demonstrating reduction in the proliferation of GVHD T lymphocytes by 66.6±7.1% to 75.8±7.0% (mean±SEM; p<0.001, n=6) after their exposure to photodepletion lymphocytes at ratios of 8:1 to 1:1, respectively. The fact that immunomagnetic depletion of CD4+CD25+ T cells from lymphocytes exposed to photodepletion abrogated the inhibitory activity of both GVHD patient and healthy donor cells indicated that these Tregs harbored a CD4+CD25+ phenotype. Moreover, Treg activity was recovered upon CD4+CD25+ cell repletion. Treg survival to photodepletion relied on P-glycoprotein induced efflux of TH9402 since inhibition of this membrane transporter by verapamil (50 μM) induced TH9402 accumulation and Treg demise upon illumination. We found that IL-10 secretion increased when photodepletion cells were cultured with GVHD untreated cells (p<0.01) and anti-IL-10 monoclonal antibodies (mAbs) blocked their suppressive activity. TGF-β was not found to be implicated in the suppression of proliferation. Allowing cell-cell contact between photodepletion exposed lymphocytes and cGVHD cells in 3- to 6-day cultures led to doubling of Treg numbers (p<0.01, n=5) while separating photodepletion treated and untreated GVHD cells abrogated both IL-10 secretion and Treg suppressive activity. Additionally, blocking CTLA-4 ligation with anti-CTLA-4 mAbs abrogated Treg function and prevented the generation of Tregs ex vivo (p<0.05), thus identifying CTLA-4-mediated cell-cell contact as a crucial priming event for Treg function. This increase in Tregs was not caused by increased proliferation as measured by EdU labelling. Exposing isolated CD4+CD25- cells to TH9402 photodepletion itself also failed to increase the number of FOXP3 expressing cells. However Treg numbers increased when CD4+CD25- cells were incubated with CD4+CD25+ cells previously exposed to photodepletion, suggesting that photodepletion cells promote the acquisition of Treg features in CD4+CD25- T cells. This photodepletion strategy was then evaluated in 5 patients suffering from refractory chronic GVHD. The patients had their cells collected by lymphopheresis, exposed to photodepletion and reinfused back into them on a weekly basis. Interestingly, the frequency of circulating Tregs in cGVHD patients undergoing TH9402 photodepletion increased in comparison to healthy donors (p<0.05), with a doubling in their numbers in comparison to pre-treatment levels (p<0.05) as early as 2 weeks after initiating treatment and these patients' conditions improved. In conclusion, these results identify a new approach to both preserve and expand Tregs while selectively eliminating CD4+ effector T cells. They also uncover effector pathways that could be used advantageously for the treatment of patients with refractory GVHD. Disclosures: Egeler: Kiadis Pharma: Employment. Roy:Kiadis Pharma: Research Funding.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".